2
|
11
|
7cxhB |
The ligand-free structure of human ppargamma lbd q286e mutant in the presence of the src-1 coactivator peptide |
104
|
274
|
7cxhA |
The ligand-free structure of human ppargamma lbd q286e mutant in the presence of the src-1 coactivator peptide |
98
|
273
|
7cxkA |
The ligand-free structure of human ppargamma lbd r288h mutant in the presence of the src-1 coactivator peptide |
99
|
273
|
7cxeA |
The ligand-free structure of human ppargamma lbd r280c mutant |
94
|
270
|
7cxjA |
The ligand-free structure of human ppargamma lbd r288c mutant in the presence of the src-1 coactivator peptide |
92
|
271
|
7cxlA |
The ligand-free structure of human ppargamma lbd s289c mutant in the presence of the src-1 coactivator peptide |
3
|
11
|
7cxfB |
The ligand-free structure of human ppargamma lbd c285y mutant in the presence of the src-1 coactivator peptide |
3
|
11
|
7cxkB |
The ligand-free structure of human ppargamma lbd r288h mutant in the presence of the src-1 coactivator peptide |
103
|
272
|
7cxfA |
The ligand-free structure of human ppargamma lbd c285y mutant in the presence of the src-1 coactivator peptide |
101
|
273
|
7cxgA |
The ligand-free structure of human ppargamma lbd q286e mutant |
3
|
11
|
7cxiB |
The ligand-free structure of human ppargamma lbd f287y mutant in the presence of the src-1 coactivator peptide |
3
|
11
|
7cxlB |
The ligand-free structure of human ppargamma lbd s289c mutant in the presence of the src-1 coactivator peptide |
96
|
271
|
7cxiA |
The ligand-free structure of human ppargamma lbd f287y mutant in the presence of the src-1 coactivator peptide |
3
|
11
|
7cxjB |
The ligand-free structure of human ppargamma lbd r288c mutant in the presence of the src-1 coactivator peptide |
91
|
275
|
7a7hA |
Crystal structure of ppargamma in complex with compound tk90 |
97
|
268
|
7efqA |
Crystal structure of hppargamma ligand binding domain complexed with rosiglitazone-based fluorescence probe |
101
|
276
|
6t1sA |
Ppar mutant |
1
|
10
|
6t1vC |
Pparg mutant |
99
|
268
|
6t1vA |
Pparg mutant |
92
|
269
|
7lotA |
Human ppar gamma lbd in complex with tetrazole compound n-{3-[(4-methylbenzyl)oxy]benzyl}-2h-tetrazol-5-amine. |
97
|
269
|
6vznA |
Crystal structure of human ppargamma ligand binding domain y473e mutant |
94
|
268
|
6vzmA |
Crystal structure of human ppargamma ligand binding domain y473e mutant in complex with darglitazone |
95
|
268
|
6vzlA |
Crystal structure of human ppargamma ligand binding domain in complex with gw1929 |
94
|
270
|
6vzoA |
Crystal structure of human ppargamma ligand binding domain (protein delipidated by denature and refold) |
93
|
268
|
7jqgA |
Crystal structure of human ppargamma ligand binding domain y473e mutant in complex with gw1929 |
94
|
268
|
6zlyA |
Crystal structure of the complex between ppargamma lbd and the ligand nv1362 (7a) |
105
|
276
|
7awdA |
Crystal structure of peroxisome proliferator-activated receptor gamma (pparg)in complex with garcinoic acid |
107
|
277
|
7awcA |
Crystal structure of peroxisome proliferator-activated receptor gamma (pparg)in complex with rosiglitazone |
96
|
274
|
6tdcA |
Ppar gamma ligand binding domain in complex with mrl-871 |
96
|
275
|
7ahjA |
Crystal structure of ppargamma v290m mutant ligand binding domain in complex with farglitazar |
100
|
273
|
6l89A |
Human ppargamma ligand binding domain complexed with butyrolactone 1 |
103
|
273
|
6l8bA |
The ligand-free structure of human ppargamma lbd |
99
|
273
|
6tsgA |
Crystal structure of peroxisome proliferator-activated receptor gamma (pparg) in complex with tetrac |
98
|
275
|
6y3uA |
Crystal structure of ppargamma in complex with compound (r)-16 |
97
|
271
|
6onjA |
Crystal structure of ppargamma ligand binding domain in complex with trap220 peptide and agonist rosiglitazone |
3
|
13
|
6pdzC |
Crystal structure of ppargamma ligand binding domain in complex with smrt peptide and inverse agonist t0070907 |
96
|
271
|
6pdzA |
Crystal structure of ppargamma ligand binding domain in complex with smrt peptide and inverse agonist t0070907 |
97
|
275
|
6oniB |
Crystal structure of ppargamma ligand binding domain in complex with n-cor peptide and inverse agonist t0070907 |
2
|
14
|
6onjC |
Crystal structure of ppargamma ligand binding domain in complex with trap220 peptide and agonist rosiglitazone |
4
|
13
|
6oniD |
Crystal structure of ppargamma ligand binding domain in complex with n-cor peptide and inverse agonist t0070907 |
93
|
268
|
6t9cA |
Crystal structure of the complex between ppargamma lbd and the ligand nv1346 (3a) |
99
|
269
|
6jeyA |
Covalent bond formation between ynone moiety of synthetic fatty acid and hpparg-lbd |
91
|
269
|
6jf0A |
Covalent labeling of hpparg-lbd by turn-on fluorescent probe mediated by conjugate addition and cyclization |
102
|
273
|
6ktmA |
The ligand-free structure of human ppargamma ligand-binding domain r288a mutant in the presence of the src-1 coactivator peptide |
99
|
272
|
6ktnA |
Human ppargamma ligand-binding domain r288a mutant in complex with imatinib |
95
|
268
|
6qj5A |
X-ray structure of ppargamma lbd with the ligand nv1380 |
3
|
11
|
6ktnB |
Human ppargamma ligand-binding domain r288a mutant in complex with imatinib |
3
|
10
|
6ktmB |
The ligand-free structure of human ppargamma ligand-binding domain r288a mutant in the presence of the src-1 coactivator peptide |
101
|
275
|
6t6bA |
Crystal structure of ppargamma in complex with compound 16 (mf27) |
98
|
268
|
6o67A |
Crystal structure of human ppargamma ligand binding domain in complex with mitoglitazone |